Can a lupus drug shield organs from Long-Term harm?

NCT ID NCT06485674

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at whether the drug anifrolumab, when added to standard lupus treatments, can reduce long-term organ damage compared to standard care alone. Researchers analyzed data from 561 adults with active lupus, comparing those who took anifrolumab in earlier trials to similar patients from a real-world clinic. The goal was to see if anifrolumab helps prevent irreversible damage to organs like the kidneys and heart.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anifrolumab
What this could lead to: If successful, this could show that anifrolumab helps prevent or slow long-term organ damage in people with active lupus.
What could go wrong: This is an observational study using data from past trials and a real-world clinic, not a new randomized trial. Results may not prove cause and effect, and benefits may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG-TERM ORGAN DAMAGE IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG-TERM ORGAN DAMAGE IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Show contact details

Locations

Research Site

Toronto, Ontario, M5G 1L7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.